2025-2029年全球製药业生成式人工智慧市场

预计 2024 年至 2029 年间，全球製药领域生成式人工智慧市场规模将成长 53.808 亿美元，预测期内复合年增长率为 26.1%。

本报告对全球製药业的生成式人工智慧市场进行了全面分析，包括市场规模和预测、趋势、成长要素和挑战，以及对约 25 家公司的供应商分析。

本报告对当前市场格局、最新趋势和驱动因素以及整体市场环境进行了最新分析，而整体市场环境的驱动因素包括加速药物发现和开发、增加个人化医疗和治疗以及优化临床试验。

本研究采用客观的方法，结合一手和二手讯息，包括来自主要行业相关人员的意见。报告包含对主要企业的分析、全面的市场规模数据、区域細項分析以及供应商格局。报告提供历史数据和预测数据。

研究指出，创新性的医疗和监管文件是未来几年推动全球製药业生成式人工智慧市场成长的关键因素之一。此外，製药行销和商业化的转型，以及製药生产和供应链管理的改进，预计也将显着提升市场需求。

目录

第一章执行摘要

第二章 Technavio 分析

• 价格、生命週期、顾客购买篮、采用率和购买标准分析
• 投入与差异化因素的重要性
• 混淆来源
• 驱动因素和挑战的影响

第三章 市场情势

• 市场生态系统
• 市场特征
• 价值链分析

第四章 市场规模

• 市场定义
• 市场区隔分析
• 2024年市场规模
• 2024-2029年市场展望

第五章 市场规模表现

• 2019-2023年全球製药业生成式人工智慧市场
• 方法细分市场分析 2019-2023
• 应用细分市场分析 2019-2023
• 2019-2023年技术细分市场分析
• 2019-2023年区域细分市场分析
• 2019-2023年国家细分市场分析

第六章五力分析

• 五力分析概述
• 买方的议价能力
• 供应商的议价能力
• 新进入者的威胁
• 替代品的威胁
• 竞争威胁
• 市场状况

第七章 依方法进行市场区隔

• 比较：依方法
• 文字生成
• 影像生成
• 语音生成
• 按方法论分類的市场机会

第八章 按应用进行市场细分

• 比较：透过应用
• 商业的
• 药物发现
• 临床开发
• 研究与开发
• 手术
• 按应用分類的市场机会

9. 按技术分類的市场细分

• 比较：按技术
• 深度学习模型
• 自然语言处理
• 生成对抗网络
• 变分自编码器
• 其他的
• 科技市场机会

第十章 客户情况

第十一章 区域情势

• 区域细分
• 区域比较
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 荷兰
  • 西班牙
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 印尼
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非
  • 以色列
  • 土耳其
• 南美洲
  • 巴西
  • 阿根廷
  • 哥伦比亚
• 各区域的市场机会

第十二章：驱动因素、挑战与机会

• 市场驱动因素
• 市场挑战
• 驱动因素和挑战的影响
• 市场机会

第十三章 竞争格局

• 概述
• 竞争格局
• 令人困惑的局面
• 产业风险

第十四章 竞争分析

• 公司简介
• 企业排名指数
• 公司市场定位
• AstraZeneca Plc
• Atomwise Inc.
• Bayer AG
• BenevolentAI
• BioXcel Therapeutics Inc.
• Deep Genomics Inc.
• Exscientia plc
• Insilico Medicine
• PathAI Inc.
• Recursion Pharmaceuticals Inc.
• Relay Therapeutics Inc.
• Sanofi SA
• Schrodinger Inc.
• Shenzhen Jingtai Technology Co.Ltd
• Valo Health

第十五章附录

The global generative AI in pharmaceutical industry market is forecasted to grow by USD 5380.8 mn during 2024-2029, accelerating at a CAGR of 26.1% during the forecast period. The report on the global generative AI in pharmaceutical industry market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by accelerating drug discovery and development, enhancing personalized medicine and treatment, optimizing clinical trials.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global generative AI in pharmaceutical industry market is segmented as below:

By Method

• Text generation
• Image generation
• Audio generation

By Application

• Commercial
• Drug discovery
• Clinical development
• Research and development
• Operations

By Technology

• Deep learning models
• Natural language processing
• Generative adversarial networks
• Variational autoencoders
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • The Netherlands
  • Spain
• APAC
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
• Middle East and Africa
  • UAE
  • South Africa
  • Turkey
• South America
  • Brazil
  • Argentina
  • Colombia
• Rest of World (ROW)

This study identifies the revolutionizing medical and regulatory writing as one of the prime reasons driving the global generative AI in pharmaceutical industry market growth during the next few years. Also, transforming pharmaceutical marketing and commercialization and enhancing pharmaceutical manufacturing and supply chain management will lead to sizable demand in the market.

The report on the global generative AI in pharmaceutical industry market covers the following areas:

• Global generative AI in pharmaceutical industry market sizing
• Global generative AI in pharmaceutical industry market forecast
• Global generative AI in pharmaceutical industry market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global generative AI in pharmaceutical industry market vendors that include AstraZeneca Plc, Atomwise Inc., Bayer AG, BenevolentAI, BioXcel Therapeutics Inc., Deep Genomics Inc., Exscientia plc, Insilico Medicine, PathAI Inc., Recursion Pharmaceuticals Inc., Relay Therapeutics Inc., Sanofi SA, Schrodinger Inc., Shenzhen Jingtai Technology Co.Ltd, Valo Health. Also, the global generative AI in pharmaceutical industry market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Method
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by Technology
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2024
• 4.4 Market outlook: Forecast for 2024-2029

5 Historic Market Size

• 5.1 Global Generative AI In Pharmaceutical Industry Market 2019 - 2023
  • Historic Market Size - Data Table on Global Generative AI In Pharmaceutical Industry Market 2019 - 2023 ($ million)
• 5.2 Method segment analysis 2019 - 2023
  • Historic Market Size - Method Segment 2019 - 2023 ($ million)
• 5.3 Application segment analysis 2019 - 2023
  • Historic Market Size - Application Segment 2019 - 2023 ($ million)
• 5.4 Technology segment analysis 2019 - 2023
  • Historic Market Size - Technology Segment 2019 - 2023 ($ million)
• 5.5 Geography segment analysis 2019 - 2023
  • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
• 5.6 Country segment analysis 2019 - 2023
  • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Five Forces Analysis

• 6.1 Five forces summary
  • Five forces analysis - Comparison between 2024 and 2029
• 6.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2024 and 2029
• 6.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
• 6.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2024 and 2029
• 6.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2024 and 2029
• 6.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2024 and 2029
• 6.7 Market condition

7 Market Segmentation by Method

• 7.1 Market segments
• 7.2 Comparison by Method
• 7.3 Text generation - Market size and forecast 2024-2029
• 7.4 Image generation - Market size and forecast 2024-2029
• 7.5 Audio generation - Market size and forecast 2024-2029
• 7.6 Market opportunity by Method
  • Market opportunity by Method ($ million)

8 Market Segmentation by Application

• 8.1 Market segments
• 8.2 Comparison by Application
• 8.3 Commercial - Market size and forecast 2024-2029
• 8.4 Drug discovery - Market size and forecast 2024-2029
• 8.5 Clinical development - Market size and forecast 2024-2029
• 8.6 Research and development - Market size and forecast 2024-2029
• 8.7 Operations - Market size and forecast 2024-2029
• 8.8 Market opportunity by Application
  • Market opportunity by Application ($ million)

9 Market Segmentation by Technology

• 9.1 Market segments
• 9.2 Comparison by Technology
• 9.3 Deep learning models - Market size and forecast 2024-2029
• 9.4 Natural language processing - Market size and forecast 2024-2029
• 9.5 Generative adversarial networks - Market size and forecast 2024-2029
• 9.6 Variational autoencoders - Market size and forecast 2024-2029
• 9.7 Others - Market size and forecast 2024-2029
• 9.8 Market opportunity by Technology
  • Market opportunity by Technology ($ million)

10 Customer Landscape

• 10.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

11 Geographic Landscape

• 11.1 Geographic segmentation
• 11.2 Geographic comparison
• 11.3 North America - Market size and forecast 2024-2029
  • 11.3.1 US - Market size and forecast 2024-2029
  • 11.3.2 Canada - Market size and forecast 2024-2029
  • 11.3.3 Mexico - Market size and forecast 2024-2029
• 11.4 Europe - Market size and forecast 2024-2029
  • 11.4.1 Germany - Market size and forecast 2024-2029
  • 11.4.2 France - Market size and forecast 2024-2029
  • 11.4.3 UK - Market size and forecast 2024-2029
  • 11.4.4 Italy - Market size and forecast 2024-2029
  • 11.4.5 The Netherlands - Market size and forecast 2024-2029
  • 11.4.6 Spain - Market size and forecast 2024-2029
• 11.5 APAC - Market size and forecast 2024-2029
  • 11.5.1 China - Market size and forecast 2024-2029
  • 11.5.2 India - Market size and forecast 2024-2029
  • 11.5.3 Japan - Market size and forecast 2024-2029
  • 11.5.4 South Korea - Market size and forecast 2024-2029
  • 11.5.5 Australia - Market size and forecast 2024-2029
  • 11.5.6 Indonesia - Market size and forecast 2024-2029
• 11.6 Middle East and Africa - Market size and forecast 2024-2029
  • 11.6.1 Saudi Arabia - Market size and forecast 2024-2029
  • 11.6.2 UAE - Market size and forecast 2024-2029
  • 11.6.3 South Africa - Market size and forecast 2024-2029
  • 11.6.4 Israel - Market size and forecast 2024-2029
  • 11.6.5 Turkey - Market size and forecast 2024-2029
• 11.7 South America - Market size and forecast 2024-2029
  • 11.7.1 Brazil - Market size and forecast 2024-2029
  • 11.7.2 Argentina - Market size and forecast 2024-2029
  • 11.7.3 Colombia - Market size and forecast 2024-2029
• 11.8 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

12 Drivers, Challenges, and Opportunity

• 12.1 Market drivers
  • Accelerating drug discovery and development
  • Enhancing personalized medicine and treatment
  • Optimizing clinical trials
• 12.2 Market challenges
  • Data privacy and security imperatives in era of accelerated innovation
  • Navigating evolving regulatory and compliance gauntlet
  • Confronting ethical dilemmas and algorithmic bias
• 12.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029
• 12.4 Market opportunities
  • Revolutionizing medical and regulatory writing
  • Transforming pharmaceutical marketing and commercialization
  • Enhancing pharmaceutical manufacturing and supply chain management

13 Competitive Landscape

• 13.1 Overview
• 13.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 13.3 Landscape disruption
  • Overview on factors of disruption
• 13.4 Industry risks
  • Impact of key risks on business

14 Competitive Analysis

• 14.1 Companies profiled
  • Companies covered
• 14.2 Company ranking index
  • Company ranking index
• 14.3 Market positioning of companies
  • Matrix on companies position and classification
• 14.4 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • SWOT
• 14.5 Atomwise Inc.
  • Atomwise Inc. - Overview
  • Atomwise Inc. - Product / Service
  • Atomwise Inc. - Key offerings
  • SWOT
• 14.6 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 14.7 BenevolentAI
  • BenevolentAI - Overview
  • BenevolentAI - Product / Service
  • BenevolentAI - Key offerings
  • SWOT
• 14.8 BioXcel Therapeutics Inc.
  • BioXcel Therapeutics Inc. - Overview
  • BioXcel Therapeutics Inc. - Product / Service
  • BioXcel Therapeutics Inc. - Key offerings
  • SWOT
• 14.9 Deep Genomics Inc.
  • Deep Genomics Inc. - Overview
  • Deep Genomics Inc. - Product / Service
  • Deep Genomics Inc. - Key offerings
  • SWOT
• 14.10 Exscientia plc
  • Exscientia plc - Overview
  • Exscientia plc - Product / Service
  • Exscientia plc - Key offerings
  • SWOT
• 14.11 Insilico Medicine
  • Insilico Medicine - Overview
  • Insilico Medicine - Product / Service
  • Insilico Medicine - Key offerings
  • SWOT
• 14.12 PathAI Inc.
  • PathAI Inc. - Overview
  • PathAI Inc. - Product / Service
  • PathAI Inc. - Key offerings
  • SWOT
• 14.13 Recursion Pharmaceuticals Inc.
  • Recursion Pharmaceuticals Inc. - Overview
  • Recursion Pharmaceuticals Inc. - Product / Service
  • Recursion Pharmaceuticals Inc. - Key offerings
  • SWOT
• 14.14 Relay Therapeutics Inc.
  • Relay Therapeutics Inc. - Overview
  • Relay Therapeutics Inc. - Product / Service
  • Relay Therapeutics Inc. - Key offerings
  • SWOT
• 14.15 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 14.16 Schrodinger Inc.
  • Schrodinger Inc. - Overview
  • Schrodinger Inc. - Business segments
  • Schrodinger Inc. - Key offerings
  • Schrodinger Inc. - Segment focus
  • SWOT
• 14.17 Shenzhen Jingtai Technology Co.Ltd
  • Shenzhen Jingtai Technology Co.Ltd - Overview
  • Shenzhen Jingtai Technology Co.Ltd - Product / Service
  • Shenzhen Jingtai Technology Co.Ltd - Key offerings
  • SWOT
• 14.18 Valo Health
  • Valo Health - Overview
  • Valo Health - Product / Service
  • Valo Health - Key offerings
  • SWOT

15 Appendix

• 15.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 15.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 15.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 15.4 Research methodology
  • Research methodology
• 15.5 Data procurement
  • Information sources
• 15.6 Data validation
  • Data validation
• 15.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 15.8 Data synthesis
  • Data synthesis
• 15.9 360 degree market analysis
  • 360 degree market analysis
• 15.10 List of abbreviations
  • List of abbreviations